moxifloxacin has been researched along with Acinetobacter Infections in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamprecht, A; Higgins, PG; Schneiders, T; Seifert, H | 1 |
| Gomez-Gutierrez, P; Lupala, CS; Perez, JJ | 1 |
| Spence, RP; Towner, KJ | 1 |
| Choi, MK; Fish, DN; Husain, M; Jung, R | 1 |
| Edmond, M; Heinemann, B; Seifert, H; Wisplinghoff, H | 1 |
| Calvo, A; García, R; Gómez-Lus, ML; Leturia, A; Sevillano, D; Valero, E | 1 |
6 other study(ies) available for moxifloxacin and Acinetobacter Infections
| Article | Year |
|---|---|
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Bacterial Proteins; Carbapenems; Drug Resistance, Bacterial; Fatal Outcome; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Molecular determinants of the bacterial resistance to fluoroquinolones: a computational study.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Molecular Docking Simulation; Moxifloxacin; Pneumococcal Infections; Point Mutation; Quinolines; Streptococcus pneumoniae | 2013 |
Frequencies and mechanisms of resistance to moxifloxacin in nosocomial isolates of Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aza Compounds; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 2003 |
Synergistic activities of moxifloxacin combined with piperacillin-tazobactam or cefepime against Klebsiella pneumoniae, Enterobacter cloacae, and Acinetobacter baumannii clinical isolates.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Colony Count, Microbial; Drug Synergism; Enterobacter cloacae; Enterobacteriaceae Infections; Enzyme Inhibitors; Fluoroquinolones; Humans; Klebsiella Infections; Klebsiella pneumoniae; Moxifloxacin; Penicillanic Acid; Penicillins; Piperacillin; Quinolines; Tazobactam | 2004 |
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Outbreaks; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Germany; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2000 |
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
Topics: Acinetobacter; Acinetobacter Infections; Ampicillin; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Opportunistic Infections; Quinolines; Sulbactam; Thienamycins | 2001 |